David R. Epstein - 08 Oct 2026 Form 4 Insider Report for AgomAb Therapeutics NV (AGMB)

Reporting relationship
Director
Issuer ticker
AGMB
Reported as of
08 Oct 2026
Net transaction value
+$44,500
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
09 Oct 2026, 08:01:30 UTC
Prior SEC filing
07 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
Ellen Lefever, Attorney-in-fact

Key filing fact

David R. Epstein filed Form 4 for AgomAb Therapeutics NV (AGMB) on 09 Oct 2026.

Key facts

  • This page summarizes David R. Epstein's Form 4 filing for AgomAb Therapeutics NV (AGMB).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 09 Oct 2026, 08:01.

Change

  • Previous filing in this sequence was filed on 07 Oct 2026.
  • Current net transaction value: +$44,500.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001445826 Primary reporting owner

Epstein David R

Relationship
Director
Address
C/O AGOMAB THERAPEUTICS NV, POSTHOFLEI 1/6, ANTWERP, BELGIUM
Signature
Ellen Lefever, Attorney-in-fact
Signature date
09 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AGMB transaction

Common shares

Purchase

Transaction value
$44,500
Shares
+5,000
Change %
+50%
Price
$8.90
Shares after
15,000
Date
08 Oct 2026
Ownership
Direct
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The common shares may be represented by American Depositary Shares, each of which currently represents one common share.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .